https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3AClostridium_butyricum%2F6%2FenTranslations:Clostridium butyricum/6/en - Revision history2026-09-13T21:56:57ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Clostridium_butyricum/6/en&diff=140412&oldid=prevFuzzyBot: Importing a new version from external source2024-04-17T11:42:46Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>CBM 588 was approved for clinical use in humans by the Japanese Ministry of Health and Welfare in 1970. The standard preparation as marketed by Miyarisan Pharmaceutical (Tokyo, Japan) consists of white, marked tablets each containing 0.35 × 10<sup>6</sup> colony forming units (CFU) of ''C. butyricum'' MIYAIRI 588 (as active agent). CBM 588 does not establish permanently in the gut, in common with other orally administered probiotic bacteria. CBM 588 for clinical use is produced by submerged anaerobic fermentation followed by centrifugation, drying, blending and packaging.</div>FuzzyBot